Clinical Trials Logo

Stress Disorders, Post-Traumatic clinical trials

View clinical trials related to Stress Disorders, Post-Traumatic.

Filter by:

NCT ID: NCT00237393 Completed - PTSD Clinical Trials

Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)

PTSD
Start date: August 2003
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine if quetiapine is effective in the treatment of PTSD.

NCT ID: NCT00230893 Completed - PTSD Clinical Trials

Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years

Start date: July 2005
Phase: N/A
Study type: Observational

The primary objective is to examine the percentage of patients with PTSD who were prescribed an antipsychotic over the past seven years in the VA Network 7 (AL, GA, SC) and compare the percentage on an annual basis. We will also determine the type and dose of antipsychotics received. We hypothesize that there has been a significant increase in antipsychotic use, especially atypical antipsychotics, prescribed for patients with PTSD over the last 7 years

NCT ID: NCT00229372 Completed - Clinical trials for Posttraumatic Stress Disorder

Prolonged Exposure Versus Treatment as Usual in Chronic Posttraumatic Stress Disorder Combat and Terror Related Patients

Start date: November 2006
Phase: N/A
Study type: Interventional

Assessing the efficacy of Posttraumatic Stress Disorder (PE) treatment for chronic Posttraumatic Stress Disorder (PTSD)

NCT ID: NCT00229359 Completed - PTSD Clinical Trials

Characteristics of Post-Traumatic Stress Disorder (PTSD) and Non-PTSD Subjects

Start date: January 2000
Phase: N/A
Study type: Observational

Compare PTSD and non-PTSD subjects on several demographic, cognitive and military variables

NCT ID: NCT00229307 Completed - PTSD Clinical Trials

Prolonged Exposure (PE) Treatment for Post Traumatic Stress Disorder (PTSD) 20 Minutes Versus 40 Minutes

Start date: December 2005
Phase: N/A
Study type: Interventional

Comparing the efficacy of 40 minutes PE treatment to 20 minutes of the same treatment

NCT ID: NCT00229294 Completed - Clinical trials for Major Depressive Disorder

Fibromyalgia in Men Suffering From PTSD

Start date: March 2004
Phase: N/A
Study type: Observational

Assessing FM and psychiatric state among PTSD, MDD and healthy participants

NCT ID: NCT00227357 Completed - HIV Infections Clinical Trials

The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

BUP
Start date: July 2005
Phase: N/A
Study type: Observational

The goal of this study is to develop and evaluate an innovative model of care to better serve patients who are both HIV-infected and opioid-dependent.

NCT ID: NCT00218959 Completed - Clinical trials for Posttraumatic Stress Disorder

Randomized Controlled Trial of Narrative Exposure Therapy Compared to Treatment as Usual for Traumatized Refugees

Start date: September 2005
Phase: N/A
Study type: Interventional

In this study we want to compare Narrative Exposure Therapy to Treatment as Usual for traumatized refugees and asylum seekers in the Mid- Norway region. Clinicians in psychiatric outpatient clinics will deliver the two conditions to asylum seekers and refugees that qualifies for Posttraumatic Stress Disorder. We will investigate if refugees and asylum seekers will improve more with Narrative Exposure Therapy or Treatment as Usual, and if there will be any differences between improvement for asylum seekers compared to improvement for refugees with residential status.

NCT ID: NCT00215878 Completed - Clinical trials for Posttraumatic Stress Disorder

D-serine for Posttraumatic Stress Disorder Treatment

Start date: August 2003
Phase: Phase 2
Study type: Interventional

The aim of this study is to asses the effects of the NMDA receptor full agonist D-serine while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress disorder (PTSD). Dysfunction of neurotransmission mediated at NMDA receptor plays a cardinal role in the pathophysiology of PTSD and PTSD patients typically suffer from cognitive dysfunctions and avoidance& depressive symptomatology that may be mediated by NMDA receptor function deficits. Thus, enhancement of NMDA activity by using D-serine may be beneficial in the treatment of PTSD. The study design involves two 6 week periods during which the participants will be randomly assigned to receive treatment with D-serine (~2g /dy)and placebo. This design allows each participant the opportunity to respond to the experimental treatment.

NCT ID: NCT00215241 Completed - Clinical trials for Post-Traumatic Stress Disorder

Risperidone Augmentation for PTSD

Start date: April 2004
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to (1) compare the response of civilians with Posttraumatic Stress Disorder(PTSD) currently receiving sertraline without an optimal response to risperidone augmentation vs. placebo, and (2) to evaluate the tolerability of risperidone augmentation, and (3) to identifiy predictors of response to risperidone augmentation. the hypothesis is that risperidone augmentation of sertraline treatment of PTSD is safe and effective.